

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Zoetis Inc.
USDA Vet Biologics Establishment Number	190
Product Code	1081.02
True Name	Bordetella Bronchiseptica Vaccine, Avirulent Live Culture
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Vanguard Intranasal Rapid RESP B - No distributor specified Vanguard Intranasal Rapid RESP B SF - No distributor specified
Date of Compilation Summary	December 07, 2017

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy									
Pertaining to	Bordetella bronchiseptica (<i>B. bronchiseptica</i>)									
Study Purpose	To demonstrate effectiveness against <i>B. bronchiseptica</i> infection									
Study I ur pose	To demonstrate effectiveness against <i>B. bronchiseptica</i> infection one year after vaccination									
Product Administration	One dose, administered intranasally									
Study Animals	Study involve	ed 16 va	accinate	ed and 16	control	puppies	s, 8 weeks of			
	age									
Challenge Description	Challenged with <i>B. bronchiseptica</i> , one year after vaccination									
Interval observed after	After challen	ge, dog	s were	observed of	daily 28	days p	ost-			
challenge	challenge.				•	• •				
Descrite										
Results										
	Number of da	we of c	oughin	n						
	Five number su									
		1			10					
	Treatment			Days Anin			-			
		Min	Q1	Median	Q3	Max	_			
	Control	4.0	10.0	18.0	25.5	28.0				
	Vaccine	0.0	1.5	4.0	9.5	20.0				
	If coughing wa	as observ	ved at ei	ther of the	two dai	ly observ	vation periods			
	on a day, that o					-	•			
	_	-	-	e	C					
	The raw data	is show	n on th	e attached	l page					
USDA Approval Date	June 20, 2014				<u> </u>					




Table 3: Individual Animal Data for Coughing Post-challenge

Key

Trt = treatment	1 = mild cough
2 = moderate cough	3 = severe cough

Study Type	Efficacy												
Pertaining to	Bordetella	Bordetella bronchiseptica (B. bronchiseptica)											
Study Purpose	To demons	To demonstrate efficacy against <i>B. bronchiseptica</i> infection											
Product	One dose, a	One dose, administered intranasally											
Administration													
Study Animals	Study invol	Study involved 16 vaccinated and 16 control puppies, 8 weeks of age											
Challenge	Challenged	Challenged with <i>B. bronchiseptica</i> , 42 days after vaccination											
Description													
Interval	After challenge, dogs were observed daily for coughing for 28 days												
observed after													
challenge													
Results	A dog was more conse <u>Table 1: C</u>	cutive	days.				t icast	Duration	2 01				
	Treatment	Total	At leas	st 1 day	of 2 consecu		Duration						
			Positive	Negative	Positive	Negative	Q1	Median	Q3				
	Control	16	16/16 (100%)	0/16 (0%)	15/16 (94%)	1/16 (6%)	18.5	22.0	23.5				
	Vaccinated	16	7/16 (44%)	9/16 (56%)	0/16 (0%)	16/16 (100%)	0	0	9.5				
	Please see a	attached	d page for	· individu	al raw data.	· · · · · · · · · · · · · · · · · · ·							
USDA	April 18, 20	013											
Approval Date	1												

ZJZ-1	ZIZ-1	ZHZ-1	YLZ-1	YIY-1	YHY-1	YGZ-1	YFZ-1	YCY-1	YBY-1	XZY-1	AVY-1	ATY-1	AJY-1	AIY-1	AGY-1	ZLY-1	ZKZ-1	YKZ-1	YJY-1	YEZ-1	YDZ-1	YAY-1	XYZ-1	WVY-1	WUZ-1	AUY-1	ASZ-1	ARZ-1	AHY-1	AFZ-1	AEZ-1		Animal
						V	ac	cir	hat	es														С	on	tro	I						Trt
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Pre- challenge	Day 4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	challeng e	_ Day 42
•	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	AM	Day 43
0 0	0	0 0	0 0	0 0	0	0 0	0	0	0 0	0	0	0 0	0 0	2 0	0	0	0	0	00	0	0	0 0	0 0	0	0	0 0	0	0 0	0	0 0	00	PM AM	
-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	•	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PM	Day 44
-	0	0	0 0	0	0	0	0	0	0	0	0	0 0	0	0	0	0	0 2	0	0	0	0	0 0	0	0	0	0	0	2 2	0	0	0 2	AM PM	Day 4
>	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	N	N	2	N	0	0	0	0	AM F	Day 46
-	0 0	0	0	0	0	0	0	0	0	0	0	00	0	0	0	0	1	20	0	0	0	2 2	2 2	2 2	2 2	2 2	2 2	2 2	0 2	0	2 2	PM AM	
-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	Ν	0	Ν	0	0	Ν	Ν	Ν	0	2	ω	2	Ν	Ν	Ν	PM	Day 47
-	0 0	0	0	0	<mark>2</mark> 0	0 0	0 0	0 0	0 0	0 0	0 0	0	0 0	0	0 0	0	1 1	0	<mark>2</mark> 0	2 2	2 2	2 2	2 2	2 2	2 2	2 2	3 2	2 2	2 2	2 2	0 2	AM PM	Day 48
-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Ν	Ν	0	Ν	2	Ν	2	0	Ν	N	A	Day 49
> >	0 0	0	00	0	0 0	0 0	0 0	0	0 0	0 0	0	00	0 0	0	<mark>2</mark> 0	0 0	0 0	0	0	0	0	2 2	2 2	<mark>2</mark> 0	0	2 2	2 2	2 2	<mark>2</mark> 0	2 2	2 2	PM AM	-
-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Ν	0	N	0	N	N	N	Ν	0	0	N	0	-	N	N	A PM	Day 5
> >	0 0	0 0	0	0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0	0 0	0	0 0	0 0	0	0	0	<mark>2</mark> 0	0	0	2 2	2 2	0	0 0	2 2	2 2	0 0	2 2	2 2	AM PM	Day 5
5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	N	0	0	0	0	N	0	N	N	0	0	N	N	-		0	AM	Day 5
> >	0	0	00	0	0	0	0	0	0	0	0	00	0	0	0 0	0 0	0 0	0	00	0	20	N	N	0	0	0	N	3 2	0	0	<mark>2</mark> 0	PM AM	Day 5
-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	N	N	0	0	0	N	2	2	0	0	0	2	2	<u>-</u>	0	N	M PM	Day 5
-	0 0	0 2	0 0	0	00	0	00	00	0	0	0	0 0	0	00	0	N	0	0 0	0 2	0 0	N	0	20	0 0	00	2	20	<mark>2</mark> 0	20	0	2 2	am Pm	Day 54
-	0	0	0	0	0	0	0	0	0	0	0 -	0	0	0	0	20	2 2	0	20	0	2 2	<mark>2</mark> 0	2	0	0	2 2	2	N	0	0	2	M AM	Davie
-	0	0	0	0	0	0	0	0	0	0	0	0	0	Ν	0	Ν	N	0	Ν	0	Ν	N	Ν	Ν	0	2	Ν	N	Ν	0	0	PM A	Day 5
-	0 0	0	0	0	0	0	0	0	0	0	0	0	0 0	0	0 0	2 2	2 2	0	1 2	0	0 2	0 2	2 2	0	0	23	2 2	2 2	0	2 2	0 1	AM PM	Day 5
•	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	N		0		0	0	N	0		0	N	N	0	0	0	0	AM F	Day 5
0 0	0 1	0	00	0	0	0	0	0	0	0	0	00	0	0	0 0	<mark>2</mark> 0	<mark>2</mark> 0	0	<mark>2</mark> 0	<mark>2</mark> 0	3 2	2 2	<mark>2</mark> 0	0	<mark>2</mark> 0	2 2	3 2	2 1	0	20	1 0	PM AM	
-	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	Ν	Ν	N	Ν	Ν	-	0	Ν	Ν	0	0	0	PM	Day 58
> >	0 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2 2	0	<mark>2</mark> 0	0	2 2	1 2	2 2	2 2	0	2 1	0	AM PM	Day 5
-	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Ν	0	0	Ν	Ν	0	Ν	0	0	Ν	2	0	0	Ν	AM	Day 6
0 0	0 0	0	0	0	0	0	0	0	0	0	0	0	0 0	0	0 0	2 0	0	0	<mark>2</mark> 0	2 2	2 2	2 2	2 2	0	<mark>2</mark> 0	0 0	0	2 2	0	0	<mark>2</mark> 0	PM AM	
-	-	0	0	0	0	0	0	0	0	0	0	0	0	Ν	Ν	-	0	Ν	0	0	Ν	Ν	Ν	Ν	Ν	0	Ν	0	0	0	Ν	PM	Day 6
0 0	0 0	0	00	0	0 0	0 0	0 0	0	0 0	0 0	0	00	0 0	0	0 0	0 0	0 0	0	2 2	0	2 2	2 2	<mark>2</mark> 0	0	1 2	0 0	2 2	<mark>2</mark> 0	0 0	0 1	<mark>2</mark> 0	AM PM	Day 62
-	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	N	0	-	0	0	N	0	0	N	A	Day 6
0	0 0	0	00	0	0 0	0 0	0 0	0 0	0 0	0	0 0	00	0 0	0	0 0	0 0	0	0	0	0	0	00	<mark>2</mark> 0	0	0	0 0	0	2 2	0 0	0 0	0	PM AM	
-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	N	0	0	0	N	PM	Day 64
-	0 0	0	00	00	0	0 0	0	20	0 0	0 0	0	00	0 0	0	0 0	0 0	<mark>2</mark> 0	00	00	0	00	0	0	00	2 2	0 0	00	<mark>2</mark> 0	0	0 0	0 0	AM PM	Day 6
-	0	0	0	0	0	0	0	0	0	0	<u>-</u>	0	0	N	0	0	0	0	N	0	0	0	0	N	0	0	0	0	0	0	0	M AM	Day 6
-	0	0	0	0	0	0 0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	2	2	0	0	0	0	0	0	0	0	PM A	Dayo
-	0 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0	0	0	0	0	0	0	0	0	0	0	<mark>2</mark> 0	<mark>2</mark> 0	<mark>2</mark> 0	<mark>2</mark> 0	0	0	AM PM	Day 67
-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	N	A	Day 6
-	0 0	0 0	0	0	0	0 0	0	0	0	0 0	0	0	0 0	0	0 0	0	0	0	1 0	0	0	0	0	0	0	0 0	0	0 0	0	1 0	0 0	PM AM	
-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Ν	0	0	0	0	0	0	0	Ν	0	0	0	0	0	0	PM	Day 69
>	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	AM	Day 70

 $\frac{\text{Key}}{\text{Trt} = \text{treatment group}} \quad 1 = \text{mild cough}$ 2 = moderate cough

3 =severe cough

Study Type	Safety										
Pertaining to	ALL										
Study Purpose	To demonstrate safety under conditions of normal use										
Product Administration	One dose, administered intranasally										
Study Animals	Study involved 674 dogs total, with 239 dogs approximately 7-9										
	weeks of age and 435 dogs 10 weeks of age or older. Dogs were										
	assigned to one of two lots of vaccine (T01- 309 animals; T02-										
Challenge Description	305 animals) or to a non-treated control group (T03- 60 animals). N/A										
Interval observed after	Immediate abnormal health events	were assessed for									
challenge	approximately 10-15 minutes post	-vaccination and late abnormal									
	health events were assessed for 14										
Results	There were no immediate post-vac										
	any of the vaccinated groups (T01										
	abnormal health events associated	with the control group (103).									
	Frequency Distribution of Late Abno	rmal Health Events with dogs									
	<u>Frequency Distribution of Late Abnormal Health Events with dogs</u> administered the product (T01 and T02)										
	Clinical Signs Associated with Number/Total Number										
	Abnormal Health Event † of Animals (%)										
	Anorexia	3/614 (0.49%)									
	Ataxia	1/614 (0.16%)									
	Cough*	7/614 (1.14%)									
	Cystitis	2/614 (0.33%)									
	Dermatitis	1/614 (0.16%)									
	Diarrhea	4/614 (0.65%)									
	Emesis*	3/614 (0.49%)									
	Emesis	5/614 (0.80%)									
	Internal ear disorder (head tilt)	1/614 (0.16%)									
	Lethargy	5/614 (0.81%)									
	Nystagmus	1/614 (0.16%)									
	Otitis externa	2/614 (0.33%)									
	Pruritis	1/614 (0.16%)									
	Pyrexia	2/614 (0.33%)									
	Rhinitis	2/614 (0.33%)									
	Sneezing*	8/614 (1.30%)									
	Urticaria**	1/614 (0.16%)									
	†One dog accounted for the abnormal health of nystagmus, lethargy, and otitis externa which to vaccination. *Mild, transient, and associated with the norm	was affirmed by licensee to not be related									

	**Urticaria occurred six days after administration of the vaccination.
USDA Approval Date	July 09, 2015